Dynamic Circulating Tumor Cell (CTC) Changes During the Chemotherapy in NSCLC (POLICE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01740804|
Recruitment Status : Completed
First Posted : December 4, 2012
Last Update Posted : December 5, 2016
Primary endpoint To observe the dynamic changes of CTC during the process of platinum based chemotherapy in advanced NSCLC.
To study the relationship between CTC count and clinical outcome of chemotherapy (ORR and PFS).
Secondary endpoint To study the relationship between CTC and overall survival. To study the molecular feature of CTC, such as epidermal growth factor receptor (EGFR), KRAS, CD117, etc.
|Condition or disease|
|Carcinoma, Non-Small-Cell Lung Cell, Circulating Tumor|
|Study Type :||Observational|
|Actual Enrollment :||180 participants|
|Official Title:||A Prospective Observational Study on the Dynamic Changes of CTC Enumeration in Advanced NSCLC With 1st Line Chemotherapy|
|Study Start Date :||November 2012|
|Actual Primary Completion Date :||April 2016|
|Actual Study Completion Date :||June 2016|
- dynamic CTC changes during chemotherapy [ Time Frame: baseline, 3 weeks and up to progression disease of chemotherapy ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01740804
|Guangdong general hospital|
|Guangzhou, Guangdong, China, 510080|
|Principal Investigator:||Yi-Long Wu, MD||Guangdong General Hospital & Guangdong Academy of Medical Sciences|